GTHX RSI Chart
Last 7 days
12.5%
Last 30 days
-11.3%
Last 90 days
-12.2%
Trailing 12 Months
45.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 84.0M | 0 | 0 | 0 |
2023 | 57.3M | 89.2M | 77.9M | 82.5M |
2022 | 24.2M | 28.1M | 46.8M | 51.3M |
2021 | 59.5M | 64.0M | 42.2M | 31.5M |
2020 | 0 | 15.4M | 30.4M | 45.3M |
2015 | 0 | 0 | 0 | 522.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 20, 2024 | thomas monica r. | acquired | - | - | 37,500 | general counsel |
Mar 20, 2024 | avagliano mark | acquired | - | - | 100,000 | chief business officer |
Mar 20, 2024 | umstead john w. v | acquired | - | - | 37,500 | chief financial officer |
Mar 18, 2024 | umstead john w. v | sold | -19,751 | 3.0169 | -6,547 | chief financial officer |
Feb 12, 2024 | malik rajesh | acquired | 8,580 | 0.3 | 28,600 | chief medical officer |
Feb 12, 2024 | malik rajesh | sold | -132,143 | 4.6204 | -28,600 | chief medical officer |
Jan 04, 2024 | malik rajesh | sold | -2,121 | 2.9423 | -721 | chief medical officer |
Jan 04, 2024 | avagliano mark | sold | -2,121 | 2.9423 | -721 | chief business officer |
Jan 04, 2024 | murdock terry l | sold | -2,121 | 2.9423 | -721 | chief operating officer |
Jan 04, 2024 | umstead john w. v | sold | -326 | 2.9423 | -111 | chief financial officer |
Which funds bought or sold GTHX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Quantbot Technologies LP | new | - | 38,016 | 38,016 | -% |
May 06, 2024 | SG Americas Securities, LLC | new | - | 58,000 | 58,000 | -% |
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -1,525 | - | -% |
May 03, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -58.59 | -32,000 | 47,000 | -% |
May 03, 2024 | SIGNATUREFD, LLC | sold off | -100 | -2,776 | - | -% |
May 02, 2024 | CHOREO, LLC | unchanged | - | 44,747 | 152,211 | -% |
May 02, 2024 | FinTrust Capital Advisors, LLC | unchanged | - | 127,991 | 435,370 | 0.08% |
May 01, 2024 | Financial Advocates Investment Management | added | 11.58 | 22,926 | 62,424 | -% |
May 01, 2024 | CAPSTONE INVESTMENT ADVISORS, LLC | added | 9.00 | 41,470 | 117,720 | -% |
May 01, 2024 | BNP PARIBAS FINANCIAL MARKETS | unchanged | - | 392 | 1,331 | -% |
Unveiling G1 Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to G1 Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.4B | 6.8B | -7.77 | 6.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.5B | 2.0B | -58.76 | 9.74 | ||||
BMRN | 15.7B | 2.5B | 76.35 | 6.35 | ||||
INCY | 12.2B | 3.8B | 16.38 | 3.24 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 524.1M | -12.77 | 10.17 | ||||
BBIO | 5.2B | 107.9M | -9.51 | 48.09 | ||||
AXSM | 3.7B | 251.0M | -12.33 | 14.56 | ||||
ARWR | 3.1B | 240.7M | -10.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -46.38 | 3.91 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.99 | 4.48 | ||||
NVAX | 645.2M | 983.7M | -1.18 | 0.66 | ||||
CRBP | 424.2M | 881.7K | -12.56 | 481.06 | ||||
INO | 259.6M | 4.9M | -1.92 | 53.35 | ||||
IBIO | 7.1M | 2.1M | -0.26 | 2.14 |
G1 Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2015Q4 |
Revenue | -2.7% | 14,476,000 | 14,873,000 | 12,300,000 | 42,392,000 | 12,946,000 | 10,250,000 | 23,576,000 | 10,573,000 | 6,902,000 | 5,796,000 | 4,858,000 | 6,604,000 | 14,218,000 | 16,546,000 | 26,599,000 | 2,140,000 | - |
Operating Expenses | -1.2% | 23,524,000 | 23,802,000 | 28,668,000 | 30,876,000 | 38,692,000 | 41,137,000 | 45,124,000 | 47,535,000 | 53,683,000 | 43,382,000 | 46,002,000 | 44,796,000 | 39,753,000 | 40,634,000 | 36,344,000 | 32,962,000 | - |
S&GA Expenses | -0.3% | 15,127,000 | 15,166,000 | 16,781,000 | 17,432,000 | 21,753,000 | 23,558,000 | 24,432,000 | 25,716,000 | 26,709,000 | 23,218,000 | 24,268,000 | 25,236,000 | 22,970,000 | 24,260,000 | 18,412,000 | 14,431,000 | - |
R&D Expenses | -0.8% | 7,318,000 | 7,380,000 | 8,811,000 | 12,040,000 | 15,480,000 | 16,587,000 | 19,581,000 | 20,843,000 | 26,305,000 | 19,790,000 | 21,143,000 | 18,752,000 | 16,540,000 | 16,374,000 | 17,932,000 | 18,531,000 | - |
EBITDA Margin | 47.9% | -0.22 | -0.43 | -0.75 | -0.73 | -2.01 | -2.68 | -3.10 | -5.86 | -6.86 | -4.58 | -3.10 | -1.56 | - | - | - | - | - |
Interest Expenses | 2.0% | 1,823,000 | 1,788,000 | 1,840,000 | 2,667,000 | 2,512,000 | 2,314,000 | 2,073,000 | 1,821,000 | 1,716,000 | 1,052,000 | 724,000 | 649,000 | 483,000 | - | - | - | - |
Income Taxes | -100.0% | - | 902,000 | 905,000 | 1,308,000 | - | 481,000 | 1,219,000 | - | - | 246,000 | 321,000 | 220,000 | 138,000 | 479,000 | 931,000 | - | - |
Earnings Before Taxes | -2.4% | -10,219,000 | -9,976,000 | -17,299,000 | 10,018,000 | -27,595,000 | -33,168,000 | -24,053,000 | -39,446,000 | -49,192,000 | -39,774,000 | -42,147,000 | -39,202,000 | -26,304,000 | -24,868,000 | -10,743,000 | -31,210,000 | - |
EBT Margin | 39.9% | -0.33 | -0.54 | -0.87 | -0.84 | -2.17 | -2.84 | -3.25 | -6.06 | -7.05 | -4.68 | -3.14 | -1.58 | - | - | - | - | - |
Net Income | 6.1% | -10,219,000 | -10,878,000 | -18,204,000 | 8,710,000 | -27,595,000 | -33,649,000 | -25,272,000 | -39,446,000 | -49,192,000 | -40,020,000 | -42,468,000 | -39,422,000 | -26,442,000 | -25,347,000 | -11,674,000 | -31,210,000 | - |
Net Income Margin | 37.4% | -0.36 | -0.58 | -0.91 | -0.87 | -2.20 | -2.88 | -3.29 | -6.08 | -7.08 | -4.71 | -3.17 | -1.61 | - | - | - | - | - |
Free Cashflow | 30.4% | -8,898,000 | -12,792,000 | -10,577,000 | 14,085,000 | -29,053,000 | -30,632,000 | -21,247,000 | -38,557,000 | -38,184,000 | -34,660,000 | -34,080,000 | -37,588,000 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -16.1% | 102 | 122 | 133 | 148 | 162 | 188 | 167 | 187 | 218 | 254 | 243 | 277 | 309 | 229 | 258 | 254 | 257 | 285 | 317 | 332 | 352 |
Current Assets | -16.6% | 96.00 | 115 | 126 | 140 | 154 | 180 | 157 | 177 | 208 | 244 | 233 | 266 | 297 | 216 | 246 | 240 | 244 | 271 | 303 | 328 | 349 |
Cash Equivalents | -38.3% | 20.00 | 32.00 | 53.00 | 56.00 | 68.00 | 95.00 | 93.00 | 144 | 183 | 221 | 212 | 244 | 279 | 207 | 238 | 234 | 242 | 269 | 300 | 325 | 348 |
Inventory | 0.9% | 13.00 | 12.00 | 13.00 | 16.00 | 16.00 | 16.00 | 14.00 | 14.00 | 8.00 | 3.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - |
Net PPE | -8.2% | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 2.00 | 1.00 |
Liabilities | -13.8% | 74.00 | 86.00 | 90.00 | 90.00 | 117 | 119 | 121 | 121 | 118 | 111 | 65.00 | 64.00 | 63.00 | 51.00 | 61.00 | 50.00 | 27.00 | 29.00 | 31.00 | 19.00 | 13.00 |
Current Liabilities | 9.7% | 33.00 | 30.00 | 34.00 | 34.00 | 34.00 | 36.00 | 37.00 | 37.00 | 35.00 | 28.00 | 27.00 | 26.00 | 26.00 | 23.00 | 33.00 | 22.00 | 18.00 | 20.00 | 21.00 | 18.00 | 12.00 |
Shareholder's Equity | -21.6% | 28.00 | 35.00 | 43.00 | 58.00 | 45.00 | 69.00 | 46.00 | 66.00 | 100 | 144 | 178 | 213 | 245 | 177 | 197 | 204 | 229 | 256 | 286 | 313 | 339 |
Retained Earnings | -1.3% | -790 | -780 | -769 | -750 | -759 | -732 | -698 | -673 | -633 | -584 | -544 | -501 | -462 | -436 | -410 | -399 | -367 | -336 | -301 | -269 | -238 |
Additional Paid-In Capital | 0.3% | 818 | 815 | 812 | 808 | 805 | 801 | 744 | 739 | 734 | 728 | 723 | 715 | 708 | 613 | 608 | 603 | 597 | 592 | 588 | 582 | 577 |
Shares Outstanding | 0.6% | 52.00 | 52.00 | 52.00 | 52.00 | 52.00 | 51.00 | 43.00 | 43.00 | 43.00 | 42.00 | 42.00 | 42.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 128 | - | - | - | 209 | - | - | - | 845 | - | - | - | 821 | - | - | - | 853 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 30.4% | -8,898 | -12,792 | -10,577 | 14,085 | -29,053 | -30,632 | -21,247 | -38,557 | -38,184 | -34,660 | -34,080 | -36,488 | -26,880 | -31,508 | 3,639 | -28,848 | -27,025 | -30,011 | -25,126 | -22,888 | -21,546 |
Share Based Compensation | -20.7% | 2,546 | 3,209 | 3,655 | 3,810 | 3,836 | 4,400 | 4,785 | 5,639 | 5,765 | 5,205 | 5,528 | 5,694 | 5,892 | 4,754 | 4,922 | 4,367 | 4,727 | 4,463 | 4,441 | 3,741 | 3,804 |
Cashflow From Investing | 169.2% | 5,289 | -7,647 | 7,201 | 346 | 2,910 | -20,362 | -29,661 | -506 | - | - | - | - | - | - | - | - | - | -1,100 | -1,224 | -176 | -216 |
Cashflow From Financing | -25752.9% | -8,722 | 34.00 | 22.00 | -26,754 | -214 | 52,350 | 127 | - | 18.00 | 43,757 | 2,083 | 1,481 | 98,542 | 472 | 284 | 20,713 | 219 | 386 | 1,372 | 678 | 269 |
Condensed Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues [Abstract] | ||
Total revenues | $ 14,476 | $ 12,946 |
Operating Expenses [Abstract] | ||
Cost of goods sold | 1,079 | 1,459 |
Research and development | 7,318 | 15,480 |
Selling, general and administrative | 15,127 | 21,753 |
Total operating expenses | 23,524 | 38,692 |
Loss from operations | (9,048) | (25,746) |
Other income (expense) | ||
Interest income | 281 | 716 |
Interest expense | (1,978) | (3,089) |
Other income (expense) | 526 | 524 |
Total other income (expense), net | (1,171) | (1,849) |
Loss before income taxes | (10,219) | (27,595) |
Income tax expense | 0 | 0 |
Net loss | $ (10,219) | $ (27,595) |
Earnings Per Share [Abstract] | ||
Basic (in usd per share) | $ (0.20) | $ (0.53) |
Diluted (in usd per share) | $ (0.20) | $ (0.53) |
Weighted Average Common Shares Outstanding [Abstract] | ||
Basic (in shares) | 52,171,684 | 51,647,934 |
Diluted (in shares) | 52,171,684 | 51,647,934 |
Product sales, net | ||
Revenues [Abstract] | ||
Total revenues | $ 14,079 | $ 10,492 |
License revenue | ||
Revenues [Abstract] | ||
Total revenues | $ 397 | $ 2,454 |
Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 19,887 | $ 32,218 |
Restricted cash | 63 | 63 |
Marketable securities | 45,299 | 49,938 |
Accounts receivable and unbilled receivables, net | 11,654 | 12,687 |
Inventories, net | 12,548 | 12,442 |
Prepaid expenses and other current assets | 6,388 | 7,600 |
Total current assets | 95,839 | 114,948 |
Property and equipment, net | 1,355 | 1,476 |
Restricted cash | 187 | 187 |
Operating lease assets | 4,630 | 4,908 |
Other assets | 15 | 21 |
Total assets | 102,026 | 121,540 |
Current liabilities | ||
Accounts payable | 5,109 | 3,992 |
Accrued expenses | 17,867 | 21,893 |
Deferred revenue | 396 | 620 |
Loan payable, current portion | 5,946 | 0 |
Other current liabilities | 3,285 | 3,211 |
Total current liabilities | 32,603 | 29,716 |
Loan payable, net of current portion | 37,147 | 51,557 |
Deferred revenue | 500 | 500 |
Operating lease liabilities | 3,996 | 4,340 |
Other liabilities | 41 | 41 |
Total liabilities | 74,287 | 86,154 |
Stockholders’ equity | ||
Common stock, $0.0001 par value, 120,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 52,261,051 and 51,952,741 shares issued as of March 31, 2024, and December 31, 2023, respectively; 52,234,385 and 51,926,075 shares outstanding as of March 31, 2024, and December 31, 2023, respectively | 5 | 5 |
Treasury stock, 26,666 shares as of March 31, 2024, and December 31, 2023 | (8) | (8) |
Additional paid-in capital | 817,946 | 815,374 |
Accumulated deficit | (790,204) | (779,985) |
Total stockholders’ equity | 27,739 | 35,386 |
Total liabilities and stockholders' equity | $ 102,026 | $ 121,540 |